In a roundtable moderated by Tanya Dorff, MD, of City of Hope, panelists Michael Morris, MD, of Memorial Sloan Kettering Cancer Center; Benjamin Garmezy, MD, of Sarah Cannon Research Institute; and Yu-Wei Chen, MD, MS, of the University of California, San Diego discuss new treatments and therapy considerations in the field of castration-resistant prostate cancer. ...
CRPC
Advertisement
Latest News
In the second part of this series, the decision-making process of considering ADT and doublet or triplet therapy is weighed.
In the first segment of this roundtable series, the panelists discuss the use of PSMA PET scans and ADT for CRPC.
The primary endpoint of rPFS was maintained in both cohorts.
Dr. Dorff shares highlights from Uromigos Live 2024 and talks about the role of ADT in prostate cancer treatment.
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
In the final segment of our roundtable series, the panelists discuss the treatment of CRPC, focusing on metastatic disease.
Advertisement
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Choueiri outlines the importance of experts putting their heads together to decide on how to approach gray areas.
The panelists wrap up this peri-operative therapy session with what the envision for the future for sparing bladders.
In this third segment, the panelists discuss bladder-sparing approaches.
The second part of this four-part segment includes conversation about ctDNA in bladder cancer.
The first part of four segments from the panel session on peri-operative therapy in bladder cancer.
Dr. Dorff shares highlights from Uromigos Live 2024 and talks about the role of ADT in prostate cancer treatment.
Advertisement
Advertisement
Latest News
In the second part of this series, the decision-making process of considering ADT and doublet or triplet therapy is weighed.
In the first segment of this roundtable series, the panelists discuss the use of PSMA PET scans and ADT for CRPC.
In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.